Potentially Unintended Discontinuation of Long-term Medication Use After Elective Surgical Procedures

Chaim M. Bell, MD, PhD; Jana Bajcar, BScPhm, MScPhm, EdD; Arlene S. Bierman, MD, MS; Ping Li, PhD; Muhammad M. Mamdani, PharmD, MA, MPH; David R. Urbach, MD, MSc

Background: Transitions between health care settings represent vulnerable periods for medical error. Discontinuation of long-term medication use may occur during discharge from the hospital to the community.

Methods: We performed a population-based, cohort study using administrative records from Ontario, Canada, between April 1, 1997, and September 30, 2002. We studied all residents 66 years and older with continuous use of warfarin, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), or β-blocker ophthalmic drops for 1 or more years. Those who had an overnight hospitalization for selected elective surgical procedures were compared with 2 control groups: one that had an ambulatory procedure and one that had no procedures. All groups were assessed for the outcome of failure to renew the prescription within 6 months.

Results: Rates of drug treatment discontinuation after overnight hospitalizations, after ambulatory procedures, and after no procedures were 11.4%, 7.5%, and 4.8%, respectively, in the warfarin group; 4.0%, 3.9%, and 3.9%, respectively, in the statin group; and 8.4%, 8.9%, and 7.9%, respectively, in the ophthalmic drops group. The adjusted odds ratio (OR) was 2.6 (95% confidence interval [CI], 2.0-3.4) for discontinuation of warfarin therapy after overnight hospitalizations and 1.6 (95% CI, 1.4-1.7) after ambulatory procedures. In contrast, there was no increased risk of discontinuing treatment with either statins (OR for overnight hospitalization, 1.0 [95% CI, 0.9-1.2]; OR for ambulatory procedure, 1.0 [95% CI 1.0-1.1]) or ophthalmic drops (OR for overnight hospitalization, 1.0 [95% CI, 0.8-1.5]; OR for ambulatory procedure, 1.1 [95% CI, 1.0-1.2]).

Conclusions: Patients prescribed long-term therapy with warfarin were at risk for potentially unintended medication discontinuation after elective procedures. Patients prescribed statins or β-blocker ophthalmic drops were not at increased risk.

Arch Intern Med. 2006;166:2525-2531

Methods

This study used population-based administrative data for all 1.3 million residents of Ontario, Canada, aged 66 years and older, to select those with at least 1 year of continuous use of warfarin, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), or β-blocker ophthalmic drops. Those who had an overnight hospitalization for elective surgical procedures were compared with 2 control groups: one that had an ambulatory procedure and one that had no procedures.
(same-day) procedure and one that had neither an ambulatory procedure nor an overnight hospitalization and surgical procedure. All 3 groups were assessed for the outcome of drug discontinuation within 6 months after discharge following the procedure. The study was approved by the ethics committee of the Sunnybrook Health Sciences Centre. We used protocols of the Institute for Clinical Evaluative Sciences in Ontario to maintain data confidentiality.

### SETTING AND DATABASES

We conducted a retrospective cohort study of multiple health databases in Ontario between April 1, 1997, and September 30, 2002. Data on individuals from 4 separate databases were linked using an encrypted unique identifier. The Ontario Drug Benefit (ODB) database records data on all prescription medications dispensed to patients older than 65 years.16 The Canadian Institute for Health Information Discharge Abstract Database (DAD) contains information on all hospitalizations and procedures in Ontario hospitals. There is excellent agreement between administrative hospitalization data and chart audit.17 The Ontario Health Insurance Plan physician-billing database (OHIP) records information on physician services, including procedures and surgical procedures. The Registered Persons Database contains demographic and vital status information for each patient in Ontario. There is little basic information missing in these databases.17 Analyses are considered population-based because of the comprehensive nature of universal health insurance in Ontario.

### PATIENTS AND MEDICATIONS

To allow ascertainment of a full year of prior use, all community-dwelling patients 66 years and older who were prescribed warfarin, statins, or ophthalmologic drops continuously for 1 or more years, as identified through the ODB, were included. The “day supply” variable allowed us to estimate the intended duration of each prescription. A 100-day supply is the maximum allowable quantity of drug that can be dispensed. If subjects were dispensed a drug prior to the end of the day supply period, the excess drug supply was carried over to the next prescription’s day supply estimation. Subjects were allowed a 150% grace period on the previous day supply to refill the next prescription. For the warfarin analysis, a 200% grace period was allowed to account for possible alterations in dose due to laboratory monitoring. For example, a patient given a 30-day statin prescription would have 45 days to refill the prescription to be considered “continuously” exposed, and a patient given a 30-day warfarin prescription would have 60 days to obtain a refill. If patients did not refill their prescription for the study drug within these successive time windows, they were not considered continuous users.

We selected the long-term medications in this study because they are commonly prescribed for the elderly and represent medications in which adherence has been estimated in large populations of seniors.18-21 Also, the medications have established records of long-term efficacy.24-27 Moreover, the use of each medication drew on different aspects of our conceptual framework.28,29 Patients taking warfarin usually require active discontinuation of the drug prior to surgery because of increased bleeding risk.30,31 Failure to continue therapy with warfarin after hospital discharge therefore represents a failure to restart therapy with the medication after an intentional discontinuation. In contrast, statins do not require discontinuation prior to surgery.32 Thus, failure to continue therapy with a statin after hospital discharge represents a failure to continue therapy with the medication. Ophthalmic drops represent a different group of medications that are largely managed (initiated and doses modified) by ophthalmologists, who are generally not actively involved in the hospital care of patients admitted for nonophthalmologic procedures. We included this group as a control and did not anticipate observing differences in adherence because the therapy is not systemic and hospital-based physicians do not typically focus on these medications.

### EXPOSURES

In each of the 3 medication-based cohorts (warfarin, statins, and ophthalmologic drops), we identified 3 groups of patients: those who had an overnight hospitalization for an elective surgical procedure, those who had a same-day surgical procedure, and those who had neither an overnight hospitalization nor a same-day surgical procedure. We studied both inpatient and ambulatory procedures to separate the effect of hospitalization from the procedure itself. During hospitalization, prescribed medications are usually provided to the patient. For outpatient procedures, medication continuity is generally the responsibility of the patient. The third group provided an estimate of the baseline rate of medication discontinuation.

The overnight hospitalization group comprised patients who had 1 of 4 elective surgical procedures: transurethral resection of the prostate, hysterectomy, total knee replacement, and total hip replacement (Table 1). We selected these elective surgical procedures because they are performed commonly in seniors and involve diverse specialties. We excluded surgical procedures with complications (such as myocardial infarction, stroke, or major hemorrhage) or prolonged lengths of stay (>10 days) to avoid

<table>
<thead>
<tr>
<th>Procedure</th>
<th>CCP Code Number</th>
<th>OHIP Code</th>
<th>Database</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transurethral prostate resection</td>
<td>72.1</td>
<td>...</td>
<td>DAD</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>80.2, 80.3, 80.4</td>
<td>...</td>
<td>DAD</td>
</tr>
<tr>
<td>Total knee replacement</td>
<td>93.41</td>
<td>...</td>
<td>DAD</td>
</tr>
<tr>
<td>Total hip replacement</td>
<td>93.5</td>
<td>...</td>
<td>DAD</td>
</tr>
<tr>
<td>Lens extraction</td>
<td>27.4, 27.5, 27.6</td>
<td>$E140</td>
<td>DAD + OHIP</td>
</tr>
<tr>
<td>Inguinal hernia repair</td>
<td>65.0, 65.1, 65.2, 65.3</td>
<td>$S223</td>
<td>DAD + OHIP</td>
</tr>
<tr>
<td>Cholecystectomy</td>
<td>63.12, 63.14</td>
<td>$S287</td>
<td>DAD + OHIP</td>
</tr>
<tr>
<td>Cystoscopy</td>
<td>01.34</td>
<td>$Z606</td>
<td>DAD + OHIP</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>01.2</td>
<td>$E747</td>
<td>DAD + OHIP</td>
</tr>
<tr>
<td>Esophagogastroduodenoscopy</td>
<td>01.1</td>
<td>$Z399</td>
<td>DAD + OHIP</td>
</tr>
</tbody>
</table>

Abbreviations: CCP, Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures; DAD, Hospital Discharge Abstract Database; OHIP, Ontario Health Insurance Plan physician-billing database.
situations in which the discontinuation of the medication may have been intentional. The same-day procedure group comprised patients who had uncomplicated outpatient procedures not requiring overnight hospitalization. These included intraocular lens extraction, inguinal hernia repair, cholecystectomy, cystoscopy, colonoscopy, and esophagogastroduodenoscopy (Table 1). This group also represented diverse providers. Because many of these procedures occurred outside the hospital setting, both the hospitalization and physician billings databases were used to identify this group. The third group served as a comparator and included patients who were not hospitalized and did not undergo any of these procedures during the study period. This group was identified with the drug benefit database, and their absence of procedures and hospitalizations was verified with the hospital and physician billings databases.

INDEX DATES

Index dates were chosen for each of the 3 procedure categories. The index date for patients having an overnight hospitalization for elective surgery was the date of hospital discharge. The index date for patients having same-day procedures was the procedure date. For the group having neither an overnight hospitalization for elective surgery nor a same-day procedure, the index date was randomly assigned from the study period.

EXCLUSIONS

To isolate the effect of the exposure of interest, patients who had any overnight hospitalization or ambulatory procedure in the 6 months prior to or after the index date were excluded. Patients were also excluded if they died within 6 months following the index date or resided in long-term care facilities. Patients could be included more than once in the study.

OUTCOMES

All 3 of our selected drugs are evidence-based therapies used to decrease the risk of adverse outcomes. Therefore, we considered the discontinuation of these medications to represent a potential adverse event. Drug discontinuation, as defined by the absence of any prescription renewals in the drug benefit database within 6 months after the index date, was our primary outcome measure. A within-class change of medication (eg, between different types of statins) was not considered an outcome event. Similarly, postoperative changes in medication dose would not be considered an outcome.

COVARIATES

We controlled for confounding factors that might influence drug discontinuation. These patient-level factors included age, sex, low-income status as measured in the drug benefit program to determine copayment, and comorbid disease burden. We used the number of distinct drugs dispensed in the year prior to cohort entry as a measure of comorbidity.

STATISTICAL ANALYSIS

Separate analyses were performed for each of the 3 selected medication cohorts. In the primary analysis, we compared the risk of drug discontinuation among (1) patients who had overnight hospitalizations for surgery and (2) patients who had ambulatory procedures. The baseline rate was estimated by persons who had neither a hospitalization nor ambulatory procedure. Multivariate logistic regression was used to model the effect of hospitalization for elective surgery on drug discontinuation in each of the 3 medication cohorts and to adjust for the effect of confounding variables. The effects of exposures on the risk of drug discontinuation were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). All reported P values are 2-tailed. Statistical analyses were performed with SAS statistical software version 8.2 (SAS Institute Inc, Cary, NC).

SENSITIVITY ANALYSES: WARFARIN

For the cohort of subjects taking warfarin, sensitivity analyses were performed with and without persons having total hip and knee replacements, colonoscopy, cystoscopy, and esophagogastroduodenoscopy because these procedures may affect the decision to continue anticoagulation.

RESULTS

Over the 6-year period, 45,220 persons were included in the warfarin group, 156,172 were included in the statin group, and 32,386 were included in the β-blocker ophthalmic drops group (Table 2). The median age was 77 years (interquartile range [IQR], 73-82 years) in the warfarin group, 74 years (IQR, 71-77 years) in the statin group, and 77 years (IQR, 73-82 years) in the ophthalmic drops group. Just over half of the persons in the warfarin group were men (23,609/45,220 [52%]). Women composed the majority of the statin (85,186 of 156,172 [55%]) and ophthalmic drops (19,618/32,386 [61%]) groups.

The proportion of low-income patients in the groups ranged from about one quarter to one third. Patients in the warfarin group had the most contact with primary care providers and internal medicine specialists in the 6 months subsequent to the index date.

DRUG DISCONTINUATION

In the warfarin group, 11.4% of patients who had an overnight hospitalization for elective surgery experienced the primary outcome compared with 7.5% of patients who had an ambulatory procedure and 4.8% of patients who did not have any procedure. In the statin group, 4.0% of patients who had an overnight hospitalization for elective surgery experienced the primary outcome compared with 3.9% of patients who had an ambulatory procedure and 3.9% of patients who did not have any procedure. In the β-blocker ophthalmic drops group, 8.4% of patients who had an overnight hospitalization for elective surgery experienced the primary outcome compared with 8.9% of patients who had an ambulatory procedure and 7.9% of patients who did not have any procedure.

ADJUSTED ANALYSES

Warfarin

Patients prescribed long-term warfarin therapy who had an overnight hospitalization and surgical procedure had an adjusted OR of 2.6 (95% CI, 2.0-3.4) for the primary outcome. Patients taking warfarin who had an ambula-

©2006 American Medical Association. All rights reserved.
We estimated the risk of potentially unintended drug use discontinuation after an overnight hospitalization for elective surgery or an ambulatory procedure among patients continuously prescribed warfarin, statins, or β-blocker ophthalmic drops. After controlling for confounding factors, patients prescribed warfarin were more than twice as likely to discontinue the drug after an overnight hospitalization for elective surgery and were more than 1.5 times more likely to discontinue the drug after an ambulatory procedure compared with the general population. Having a procedure did not affect the risk of potentially unintended discontinuation of either statins or β-blocker ophthalmic drops.

Previous studies suggest that discontinuation of drug use after hospital discharge is common. However, these studies focused on changes in drug regimens rather than the discontinuation of long-term medication use. No study followed patients for longer than 1 month to determine if the drug regimens were restarted or commented on whether the use of the drugs was intentionally discontinued for clinical indications.

Why did patients receiving warfarin have an elevated risk for medication discontinuation while patients receiving statins or ophthalmic drops did not? We believe that this may relate to differences in patients’ medication-taking practices. Patients receiving warfarin are usually instructed to discontinue use of the medication prior to procedures because of concern about excessive bleeding. Patients prescribed ophthalmic drops who had an overnight hospitalization had an adjusted OR of 1.0 (95% CI, 0.8-1.5) for the primary outcome. The adjusted OR was 1.1 (95% CI, 1.0-1.2) for patients who had an ambulatory procedure. Patients prescribed ophthalmic drops who had an overnight hospitalization had a period following the operation or procedure when anticoagulation with warfarin is intentionally not resumed. Restarting anticoagulation therapy then requires active participation of the patient and physician. Further miscommunication may ensue if the physician dis-
continuing the medication therapy is different from the one expected to reinstitute therapy. Other medication therapies requiring active discontinuation and restarting in the perioperative period such as antiplatelet agents and other anticoagulants may also pose an elevated risk of discontinuation. In contrast, patients prescribed statins and ophthalmic drops are usually not instructed to discontinue the medication therapies we studied that the observed medication discontinuation was unintended. Specifically, the medication therapies we studied included patients with indications for warfarin prophylaxis for deep vein thrombosis, we required 1 year of continuous use of the drug. This requirement also minimized any confounding from patient non-adherence. Also, we used a control group without any surgical procedures or hospitalization to estimate the baseline discontinuation risk. Some may contend that the higher rate of discontinuation among the patients in the overnight hospitalization and elective procedures group could be explained by greater physician attention to the original indication for the drug and hence the drug discontinuation might be intentional. However, we excluded elective surgical procedures that were associated with postoperative complications that may result in intentional drug discontinuation. We also adjusted for internal medicine and primary care consultations. Moreover, we excluded those who were hospitalized for any reason within 6 months of the index date to avoid including patients with active medical issues. Furthermore, a sensitivity analysis that excluded patients with indications for warfarin prophylaxis yielded similar results. Finally, another study using structured implicit and explicit review of clinical data in the intensive care unit setting has also demonstrated the unintended discontinuation of many long-term medication therapies including warfarin, suggesting that our findings are not merely attributable to insufficient clinical detail. Other limitations include our reliance on administrative data. However, the databases we used are accurate and have been used previously to study medication adherence. Second, since this was an observational study, the results are susceptible to bias or confounding. However, we took care to ensure the comparability of the patient groups. Our inclusion criteria, matching strategy, use of a control group, and covariate adjustment helped to account for baseline differences. Third, we studied the phenomenon of potentially unintended medication discontinuation in the specific context of hospitalizations for certain elective surgical procedures. The risk of potentially unintended medication discontinuation in other clinical settings may be different. Fourth, the specific procedures studied in the overnight hospitalization and ambulatory groups were different, and we cannot exclude the possibility that differences in medication discontinuation are related to the procedure studied. Finally, we did not measure the effect of medication discontinuation on long-term clinical outcomes. However, it is reasonable to believe that discontinuation of medication therapies with strong evidence of clinical effectiveness compromises optimal patient care and exposes patients to potential harm.

Transitions between settings of care are an area of vulnerability for patient safety. We found that patients prescribed long-term anticoagulants are at risk for potentially unintended drug discontinuation. These findings may
extend to other types of medications as well as the broader context of care transitions after hospitalization. Better communication strategies involving hospital-based physicians, pharmacists, and nurses, their counterparts in the community, as well as the patients themselves, may reduce the risk of this phenomenon. Hospitalization should provide an opportunity to encourage medication adherence and not be a contributor to its failure.

Accepted for Publication: September 1, 2006.
Correspondence: Chaim M. Bell, MD, PhD, St Michael’s Hospital, 30 Bond St, Toronto, Ontario, Canada M5B 1W8 (bellc@smh.toronto.on.ca).

Author Contributions: Dr Bell had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Bell, Bajcar, Bierman, Mamdani, and Urbach. Acquisition of data: Bell and Li. Analysis and interpretation of data: Bell, Bajcar, Bierman, Li, Mamdani, and Urbach. Drafting of the manuscript: Bell, Bajcar, Bierman, Li, Mamdani, and Urbach. Critical revision of the manuscript for important intellectual content: Bell, Bajcar, Bierman, Li, Mamdani, and Urbach. Statistical analysis: Bell, Li, Mamdani, Urbach. Obtained funding: Bell, Bajcar, Bierman, Mamdani, and Urbach. Study supervision: Bell and Mamdani.

Financial Disclosure: Dr Mamdani is currently an employee of Pfizer Inc, the manufacturer of one statin medication. The involvement of Dr Mamdani in the development of this study and manuscript clearly preceded and was not influenced by his subsequent decision to work for Pfizer.

Funding/Support: This work was funded by an operating grant from the Canadian Institutes of Health Research. Dr Bell is the recipient of a New Investigator Award from the Institute of Aging, Canadian Institutes of Health Research. Dr Mamdani held a New Investigator Award, from the Institute of Aging, Canadian Institutes of Health Research. Dr Bajcar is the recipient of a New Investigator Award and manuscript clearly preceded and was not influenced by his subsequent decision to work for Pfizer.

Role of the Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

Acknowledgment: We thank Ed Etchells, MD, MSc, and Don Redelmeier, MD, MSc, for their helpful suggestions and careful review of the manuscript.

REFERENCES